Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Clinical trial NCT05509699 · COMPLETED
Trial details
- NCT number
- NCT05509699
- Sponsor
- Hutchison Medipharma Limited
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-27
- Primary completion
- 2024-07-31
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.